Next steps in anti-amyloid immunotherapy

Robert Vassar, PhD, Feinberg School of Medicine, Northwestern University, Chicago, IL, highlights the questions that most need answering regarding anti-amyloid immunotherapies. One important question is when to treat with these agents. With antibodies slowing down Alzheimer’s disease progression but not stopping the disease, trials are now looking into delaying or even preventing its onset altogether by using antibodies to treat patients with amyloid who have not developed symptoms. Another question is whether administration can be made easier; subcutaneous injections would be less expensive and more accessible than intravenous infusion. Lastly, Dr Vassar discusses brain shuttle techniques in development to increase the level of antibody that can be transferred across the blood-brain barrier. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.